-
![KemPharm_450x300]( "KemPharm: Converting FDA Complete Response Letters Into New Opportunities")
KemPharm: Converting FDA Complete Response Letters Into New Opportunities8/1/2022KemPharm’s experience in reworking product NDAs following FDA Complete Response Letters has created a unique capability within the company, and helped it move to acquire a potentially valuable asset from distressed biopharma Orphazyme.
-
![Feature - Rain Therapeutics_450x300]( "A Network And Pivot Model For Success In Cancer Drug Development")
A Network And Pivot Model For Success In Cancer Drug Development7/1/2022When CEO Avanish Vellanki founded and incorporated Rain Therapeutics on his living room couch in the spring of 2017, there was no drug in development, no money, and a team of only four people.
-
![Ron Cooper - Albireo_450x300]( "Transitioning To Orphan Drug Commercialization: A Q&A With Albireo Pharma's CEO Ron Cooper")
Transitioning To Orphan Drug Commercialization: A Q&A With Albireo Pharma's CEO Ron Cooper7/1/2022Albireo Pharma CEO Ron Cooper discusses the company’s three approaches to commercializing orphan drugs globally, and how to go from topline data to regulatory filing in 70 days.
-
![Ben Comer_450x300]( "Scouting Turbulence For Opportunity")
Scouting Turbulence For Opportunity7/1/2022With bad news in the headlines at home and globally, and a seesawing public market capable of wiping years of value from company books almost overnight, it can be difficult to remain focused on the bread-and-butter tasks that keep a company afloat.
-
![Feature - Arcellx_450X300]( "Leveling Up By Challenging Assumptions")
Leveling Up By Challenging Assumptions6/1/2022An outspoken champion of gender equity and diversity in the workplace, Arcellx CEO Rami Elghandour aims to put the company’s controllable CAR-T therapies on the cover of Time magazine.
-
![Ben Comer_450x300]( "From Summer Stroll To Summer Hustle")
From Summer Stroll To Summer Hustle6/1/2022As news reporter covering the biopharmaceutical industry in the early aughts, the summer months could present a different kind of challenge.
-
![Diagnostics in Neurology and Alzheimers_450x300]( "3 Approaches For Developing Better Drugs To Treat Brain Disorders")
3 Approaches For Developing Better Drugs To Treat Brain Disorders6/1/2022Three organizations pursuing three different strategies for new drug development have one thing in common: optimism about the future of treatments for intractable brain disorders.
-
![Ben Comer_450x300]( "A New Golden Age Of Psychedelic Therapy? Proceed With Caution")
A New Golden Age Of Psychedelic Therapy? Proceed With Caution5/2/2022Is it time to stop worrying and love the drugs? Psychedelic medicines promise a radical solution to endemic mental health conditions, but caution is needed to cross the finish line.
-
![Feature - MAPS_450x300]( "A New Model For A New Era Of Psychedelic Therapy")
A New Model For A New Era Of Psychedelic Therapy5/2/2022MAPS Public Benefit Corporation hopes to kick off the next golden age of psychedelic therapy with the potential FDA approval of its MDMA candidate for PTSD.
Ben Comer
Ben Comer is chief editor of Life Science Leader magazine. He has covered the biopharmaceutical, medtech and medical device industries for 15 years as a reporter and editor, and worked as a senior manager in PwC’s Health Research Institute. Comer was most recently executive editor at In Vivo magazine, where he wrote feature stories, executive profiles and articles ranging from pre-clinical biotech strategy, fundraising, supply chain, manufacturing, and regulatory issues, to global commercialization efforts, market access and environmental, social and governance topics. He has interviewed hundreds of executives and experts at biopharmaceutical and life science companies, academic institutions, law firms, patient advocacy groups, payer and provider organizations, industry trade associations and regulatory bodies. Comer has presented and moderated panels at dozens of industry conferences, convened webcasts with industry leaders, and published news articles and other writing in Scrip, Pink Sheet, MedTech Insight, Generics Bulletin, Pharmaceutical Executive, PharmTech, Applied Clinical Trials, Medical Marketing & Media and PR Week, among others. Comer is a graduate of the College of Charleston and has worked in compounding pharmacies as a certified technician. You can find him on Twitter @BenMComer.